Harmony Biosciences Holdings, Inc.
For the period ended Jun 30, 2026. Filed Aug 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 4, 2026
HRMY$33.78+2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| (a) | None. |
| (b) | None. |
| (c) | On May 14, 2026, Kumar Budur, Chief Medical and Scientific Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 61,406 shares of the Company’s common stock related to the to the exercise of options, (ii) up to 9,995 shares of the Company’s common stock related to the vesting of restricted stock units previously granted, and (iii) up to 1,005 shares of the Company’s common stock related the Company’s employee stock purchase plan, beginning on August 13, 2026, and continuing until June 30, 2027. On June 5, 2026, this plan entered into on May 14, 2026, was subsequently terminated and Kumar Budur adopted a new Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 61,406 shares of the Company’s common stock related to the to the exercise of options, (ii) up to 9,995 shares of the Company’s common stock related to the vesting of restricted stock units previously granted, and (iii) up to 1,005 shares of the Company’s common stock related the Company’s employee stock purchase plan, beginning on September 4, 2026, and continuing until June 30, 2027. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.